Review of pharmacokinetic models for target controlled infusions in anesthesia
Keywords:
Pharmacokinetic model, Target controlled infusionAbstract
Intravenous injection of anesthetic drugs dates back to the 17th Century when opium and chloral hydrate have been injected intravenously. It was not until the 1930s intravenous anesthesia became popular with the invention of barbiturates.Early intravenous anesthetic agents such as barbiturates were ideal for induction of anesthesia, but not suitable for maintenance of anesthesia. Most of these drugs accumulated significantly with increasing durations of infusion and also resulted in cardiorespiratory depression. The invention of propofol and shorter acting opioid analgesics such as remifentanil and alfentanil have revolutionized intravenous anesthesia. The rapid onset and offset of these drugs lends itself to being suitable agents for maintenance of anesthesia over prolonged periods of time.1,2 Detailed understanding of the pharmacokinetics of propofol and remifentanil, combined with technological advances in intravenous pumps capable of accurate delivery of drugs have resulted in great development of the field of total intravenous anesthesia and target controlled infusions. I would like to discuss, in this article, the pharmacokinetics and pharmacokinetic models behind these intravenous infusion pumps.
References
Doze VA, Shafer A, White PF. Propofol nitrous oxide versus thiopental isoflurane nitrous oxide for general anesthesia. Anesthesiology. 1988;69(1):63 71.
Lim BL, Low TC. Total intravenous anaesthesia versus inhalational anaesthesia for dental day surgery. Anaesth Intensive Care. 1992;20(4):475 8.
Krüger Thiemer E. Continuous intravenous infusion and multicompartment accumulation. Eur J Pharmacol. 1968;4(3):317 24.
Jacobs JR. Algorithm for optimal linear model based control with application to pharmacokinetic model driven drug delivery. IEEE Trans Biomed Eng. 1990;37(1):107 9.
Marsh B, White M, Morton N, Kenny GN. Pharmacokinetic model driven infusion of propofol in children. Br J Anaesth. 1991;67(1):41 8.
Gepts E, Camu F, Cockshott ID, Douglas EJ. Disposition of propofol administered as constant rate intravenous infusions in humans. Anesth Analg. 1987;66(12):1256 63.
Schüttler J, Ihmsen H. Population pharmacokinetics of propofol: a multicenter study. Anesthesiology. 2000;92(3):727 38.
Schnider TW, Minto CF, Gambus PL, Andresen C, Goodale DB, Shafer SL, et al. The influence of method of administration and covariates on the pharmacokinetics of propofol in adult volunteers. Anesthesiology. 1998;88(5):1170 82.
Leslie K, Crankshaw DP. Lean tissue mass is a useful predictor of induction dose requirements for propofol. Anaesth Intensive Care. 1991;19(1):57 60.
Wulfsohn NL, Joshi CW. Thiopentone dosage based on lean body mass. Br J Anaesth. 1969;41(6):516 21.
Beemer GH, Bjorksten AR, Crankshaw DP. Pharmacokinetics of atracurium during continuous infusion. Br J Anaesth. 1990;65(5):668 74.
Egan TD, Huizinga B, Gupta SK, Jaarsma RL, Sperry RJ, Yee JB, et al. Remifentanil pharmacokinetics in obese versus lean patients. Anesthesiology. 1998;89(3):562 73.
James W. Research on obesity. London: Her Majesty’s Stationery Office; 1976.
Minto CF, Schnider TW, Egan TD, Youngs E, Lemmens HJ, Gambus PL, et al. Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development. Anesthesiology. 1997;86(1):10 23.
Muñoz HR, Guerrero ME, Brandes V, Cortínez LI. Effect of timing of morphine administration during remifentanil based anaesthesia on early recovery from anaesthesia and postoperative pain. Br J Anaesth. 2002;88(6):814 8.
NICE Guidance: NICE Diagnostic Guidance, 6 Nov 2012. Available from: http://www.nice.org.uk/dg6. [Last updated on 2012 Dec 11].
Mortier E, Struys M, De Smet T, Versichelen L, Rolly G. Closed loop controlled administration of propofol using bispectral analysis. Anaesthesia. 1998;53(8):749 54.
